| Literature DB >> 35762302 |
Yi-Ming Chen1, Wei Chen2, Yue Xu3, Chao-Sheng Lu3, Mian-Mian Zhu3, Rong-Yue Sun3, Yihong Wang3, Yuan Chen3, Jiaming Shi3, Dan Wang3.
Abstract
BACKGROUND: Succinate-CoA ligase/synthetase (SCS) deficiency is responsible for encephalomyopathy with mitochondrial DNA depletion and mild methylmalonic aciduria. Variants in SUCLG1, the nuclear gene encoding the alpha subunit of the SCS enzyme playing a pivotal role in maintaining mtDNA integrity and stability, are associated with mitochondrial DNA depletion syndrome 9 (MTDPS9).Entities:
Keywords: zzm321990SUCLG1zzm321990; compound heterozygous variants; mitochondrial DNA depletion syndrome 9; mitochondrial encephlomyopathy; whole exome sequencing
Mesh:
Substances:
Year: 2022 PMID: 35762302 PMCID: PMC9482404 DOI: 10.1002/mgg3.2010
Source DB: PubMed Journal: Mol Genet Genomic Med ISSN: 2324-9269 Impact factor: 2.473
The results of proband detected in blood and urine
| Serum | Value | References |
|---|---|---|
| Glutamic‐pyruvic transaminase (ALT) (U/L) | 68 | 9–50 |
| Glutamic‐oxalacetic transaminase (AST) (U/L) | 57 | 9–50 |
| Lactic acid (mmol/L) | >12 | 0–2.0 |
| Ammonia (μmol/L) | 60 | 0–100 |
| Creatine kinase (CK) | 89 | 58–110 |
| Free carnitine (C0) (μmol/L) | 12.36 | 9.50–60.0 |
| Propionyl carnitine (C3) (μmol/L) | 3.41 | 0.40–5.00 |
| Succinylcarnitine (μmol/L) | 0.06 | 0.01–0.12 |
| Urine | ||
| Lactic acid | 256.4 | 0.0–13.0 |
| Pyruvic acid | 174.1 | 0.0–30.0 |
| Methylmalonic acid (MMA) | 13.1 | 0–4.0 |
| 3‐hydroxypropionic acid | 12.9 | 0–4.0 |
| Methylcitric acid | 1.2 | 0–0.7 |
FIGURE 1Brain MRI of the patient showed cerebral dysplasia and bilateral lateral cerebral ventriculomegaly. (a) T1W; (b) T2W; (c) DW.
FIGURE 2Pedigree of the studied family and sequence chromatograms showing the variants in SUCLG1 gene. (a) Pedigree of the studied family. (b) Sanger sequencing showing SUCLG1c.601A>G variant. (c) Sanger sequencing showing SUCLG1c.871G>C variant. The black arrow indicates the proband. The red arrows indicate variant sites.
FIGURE 3Relative mtDNA contents (MTL1/BM2) in peripheral blood of the proband and age‐matched controls. The mtDNA content of proband was normalized by mtDNA in controls.
FIGURE 4(a) Mitofates prediction in human's wild type and mutated SUCLG1 mitochondrial targeting sequences. (b) Hydrophobicity scale in SUCLG1is compared in the wildtype and mutated p.R201G and p.A291P proteins. Blue frames show changes in hydrophobicity scales.
FIGURE 5Scheme and molecular model of SUCLG1 protein. (a) Schematic view of SUCLG1 protein. Both variants reported here fall in the CoA_binding domain. (b) The scores of Polyphen‐2 Prediction of p.R201G and p.A291P on HumVar models. (c) Evolutionary conservation of the p.R201 and p.A291 from elegans to human. The positions of variants are indicated by red rectangles.
FIGURE 6Modeled structure of the human SUCLG1 protein. (a) Structure of the wildtype SUCLG1 protein. 201R and 291A residues are annotated in red font. (b,c) The hydrogen bonding network is illustrated by the yellow dashed lines surrounding R201 and A291. (b) 201R is involved in hydrogen bonds with the residues 255I, 257‐259EIG and 301G, while the 201G variation removes all the hydrogen bonds except 255I. (c) 291A may create an ionic bound with 288A, while the mutant 291P could potentially abolish that only one hydrogen bond.